Analyst Price Target is $50.00
▲ +2,790.17% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nabriva Therapeutics in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 2,790.17% upside from the last price of $1.73.
Current Consensus is
The current consensus among 1 investment analysts is to sell stock in Nabriva Therapeutics. This rating has held steady since May 2022, when it changed from a Hold consensus rating.
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.